-+ 0.00%
-+ 0.00%
-+ 0.00%

Mira Pharmaceuticals investor presentation highlights Ketamir-2 advancing to Phase 2a neuropathic pain trial

Reuters·04/06/2026 23:17:11

Please log in to view news